PALO ALTO, Calif.--(BUSINESS WIRE)--Neuvivo, a late-clinical stage biopharmaceutical company, today announced promising results from two groundbreaking publications on its investigational ...
Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results